DHDavid K. Han

David K. Han

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


David K. Han has a total of 38 co-authors. Here are the top co-authors by number of shared publications:

  • Viveka Mayya

    Kennedy Institute of Rheumatology, University of Oxford

    4 shared publications
  • Deborah H. Lundgren

    Center for Vascular Biology, Department of Cell Biology, University of Connecticut School of Medicine, Farmington, CT, USA

    3 shared publications
  • Karim Rezaul

    Department of Cell Biology, Center for Vascular Biology, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, Connecticut 06030, United States

    3 shared publications
  • Veneta Qendro

    Center for Vascular Biology, Department of Cell Biology, University of Connecticut School of Medicine, Farmington, CT, USA

    3 shared publications
  • Ardian Latifi

    Center for Vascular Biology, Department of Cell Biology, University of Connecticut School of Medicine, Farmington, CT, USA

    2 shared publications
  • Jimmy K. Eng

    Department of Genome Sciences, University of Washington

    2 shared publications

Latest Publications

  • Discovery of putative breast cancer antigens using an integrative platform of genomics‐driven immunoproteomics

    by Veneta Qendro, Deborah H. Lundgren, Samuel Palczewski, Poornima Hegde, Christina Stevenson, Laurie Perpetua, Ardian Latifi, Jesse Merriman, Grace Bugos, David K. Han

    Recent advances in cancer immuno‐therapeutics such as checkpoint inhibitors, chimeric antigen‐receptor T cells, and tumor infiltrating T cells (TIL) are now significantly impacting cancer patients in a positive manner. Although very promising, reports indicate no more than 25% of cases result in complete remission. One of the limitations of these treatments is the identity of putative cancer antigens in each patient, as it is technically challenging to identify cancer antigens in a rapid fashion. Thus, identification of cancer antigens followed by targeted treatment will increase the efficacy of cancer immunotherapies. To achieve this goal, a combined technologies platform of deep genomic sequencing and personalized immune assessment was devised, termed Genomics Driven Immunoproteomics (GDI). Using this technological platform, we report the discovery of 149 tumor antigens from human breast cancer patients. Significant number of these putative cancer antigens arise from single nucleotide variants (SNVs), as well as insertions and deletions that results into frame‐shift mutations. We propose a general model of anti‐cancer immunity and suggest that the GDI platform may help identify patient‐specific tumor antigens in a timely fashion for precision immunotherapies.


  • Integrative proteomics, genomics, and translational immunology approaches reveal mutated forms of Proteolipid Protein 1 (PLP1) and mutant‐specific immune response in multiple sclerosis

    by Veneta Qendro, Grace A. Bugos, Debbie H. Lundgren, John Glynn, May H. Han, David K. Han

    In order to gain mechanistic insights into multiple sclerosis (MS) pathogenesis, we utilized a multi‐dimensional approach to test the hypothesis that mutations in myelin proteins lead to immune activation and central nervous system autoimmunity in MS. Mass spectrometry‐based proteomic analysis of human MS brain lesions revealed seven unique mutations of PLP1; a key myelin protein that is known to be destroyed in MS. Surprisingly, in‐depth genomic analysis of two MS patients at the genomic DNA and mRNA confirmed mutated PLP1 in RNA, but not in the genomic DNA. Quantification of wild type and mutant PLP RNA levels by qPCR further validated the presence of mutant PLP RNA in the MS patients. To seek evidence linking mutations in abundant myelin proteins and immune‐mediated destruction of myelin, specific immune response against mutant PLP1 in MS patients was examined. Thus, we have designed paired, wild type and mutant peptide microarrays, and examined antibody response to multiple mutated PLP1 in sera from MS patients. Consistent with the idea of different patients exhibiting unique mutation profiles, we found that 13 out of 20 MS patients showed antibody responses against specific but not against all the mutant‐PLP1 peptides. Interestingly, we found mutant PLP‐directed antibody response against specific mutant peptides in the sera of pre‐MS controls. The results from integrative proteomic, genomic, and immune analyses reveal a possible mechanism of mutation‐driven pathogenesis in human MS. The study also highlights the need for integrative genomic and proteomic analyses for uncovering pathogenic mechanisms of human diseases.


  • Large-Scale Proteomic Characterization of Melanoma Expressed Proteins Reveals Nestin and Vimentin as Biomarkers That Can Potentially Distinguish Melanoma Subtypes

    by Veneta Qendro, Deborah H. Lundgren, Karim Rezaul, Forrest Mahony, Nicholas Ferrell, Andrew Bi, Ardian Latifi, Daniyal Chowdhury, Steven Gygi, Wilhelm Haas, et al.

    Melanoma is an aggressive type of skin cancer, which accounts for only 4% of skin cancer cases but causes around 75% of skin cancer deaths. Currently, there is a limited set of protein biomarkers that can distinguish melanoma subtypes and provide an accurate prognosis of melanoma. Thus, we have selected and profiled the proteomes of five different melanoma cell lines from different stages of progression in comparison with a normal melanocytes using tandem mass spectrometry. We also profiled the proteome of a solid metastatic melanoma tumor. This resulted in the identification of 4758 unique proteins, among which ∼200–300 differentially expressed proteins from each set were found by quantitative proteomics. Correlating protein expression with aggressiveness of each melanoma cell line and literature mining resulted in the final selection of six proteins: vimentin, nestin, fibronectin, annexin A1, dipeptidyl peptidase IV, and histone H2A1B. Validation of nestin and vimentin using 40 melanoma samples revealed pattern of protein expression can help predict melanoma aggressiveness in different subgroups of melanoma. These results, together with the combined list of 4758 expressed proteins, provide a valuable resource for selecting melanoma biomarkers in the future for the clinical and research community.


    • 20 September 2012
      • Vol. 9  (5) , 257-63

    Identification of differentially expressed proteins from primary versus metastatic pancreatic cancer cells using subcellular proteomics.

    by Kimberly Q McKinney, Jin-Gyun Lee, David Sindram, Mark W Russo, David K Han, Herbert L Bonkovsky, Sunil Hwang

    Pancreatic cancer is an aggressive disease with nearly equal yearly rates of diagnosis and death. Current therapies have failed to improve outcomes due to rapid disease progression and late stage at presentation. Recently, pathways involved in progression and metastasis have been elucidated; however, new knowledge has not generated more effective therapies. We report on the use of subcellular fractionation and liquid chromatography (LC)-mass spectrometry to identify 3,907 proteins in four pancreatic cancer cell lines, 540 of which are unique to primary cancer cells, and 487 unique to cells derived from metastatic sites. Statistical analysis identified 134 proteins significantly differentially expressed between the two populations. The subcellular localization of these proteins was determined and expression levels for four targets were validated using western blot techniques. These identified proteins can be further investigated to determine their roles in progression and metastasis and may serve as therapeutic targets in the development of more effective treatments for pancreatic cancer.


  • Phosphoproteomics by mass spectrometry: insights, implications, applications and limitations

    by Viveka Mayya, David K Han

    Phosphorylation of proteins is a predominant, reversible post-translational modification. It is central to a wide variety of physiological responses and signaling mechanisms. Recent advances have a...


  • Direct cancer tissue proteomics: a method to identify candidate cancer biomarkers from formalin-fixed paraffin-embedded archival tissues

    by S-I Hwang, J Thumar, D H Lundgren, K Rezaul, V Mayya, L Wu, J Eng, M E Wright, D K Han

    Successful treatment of multiple cancer types requires early detection and identification of reliable biomarkers present in specific cancer tissues. To test the feasibility of identifying proteins from archival cancer tissues, we have developed a methodology, termed direct tissue proteomics (DTP), which can be used to identify proteins directly from formalin-fixed paraffin-embedded prostate cancer tissue samples. Using minute prostate biopsy sections, we demonstrate the identification of 428 prostate-expressed proteins using the shotgun method. Because the DTP method is not quantitative, we employed the absolute quantification method and demonstrate picogram level quantification of prostate-specific antigen. In depth bioinformatics analysis of these expressed proteins affords the categorization of metabolic pathways that may be important for distinct stages of prostate carcinogenesis. Furthermore, we validate Wnt-3 as an upregulated protein in cancerous prostate cells by immunohistochemistry. We propose that this general strategy provides a roadmap for successful identification of critical molecular targets of multiple cancer types.


  • Open Access

    A Systematic Characterization of Mitochondrial Proteome from Human T Leukemia Cells

    by Karim Rezaul, Linfeng Wu, Viveka Mayya, Sun-Il Hwang, David Han


  • Open Access

    PROTEOME-3D: An Interactive Bioinformatics Tool for Large-Scale Data Exploration and Knowledge Discovery

    by Deborah H. Lundgren, Jimmy Eng, Michael E. Wright, David K. Han